DSSTox_CID_3143

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

25 Suppliers, 16 USDMF, 3 CEP/COS, 2 JDMF, 2 EU WC, 3 KDMF, 3 NDC API, 6 Listed Suppliers

DEVELOPMENTS

5 Drug(s) in Development

5 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

2 Suppliers

2 Suppliers

DOSSIERs // Finished Dosage Forms

47 Dossiers, 13 FDA Orange Book, 10 Europe, 6 Canada, 7 South Africa, 11 Listed Dossiers

DRUG PRODUCT COMPOSITION

POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL;250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INTRAVENOUS - EQ 500MG BASE/VIAL;500MG/VIAL

RELATED EXCIPIENT COMPANIES

Suppliers, 1 SPI Pharma

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 10 Finished Drug Prices

MARKET PLACE

13 APIs, 4 DOSSIERS // FDF

PATENTS

3 US Patents, 2 US Exclusivities

ANALYTICAL SOLUTION(s)

1 EDQM Standards, 1 USP Standards, 1 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilation & Company Tracker #PharmaFlow, 20 News

Information, Expiry, & Status of FDA Orange Book Exclusivities covering DSSTox_CID_3143

DSSTox_CID_3143

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

25 Suppliers

16 USDMF

3 CEP/COS

2 JDMF

2 EU WC

3 KDMF

3 NDC API

6 Listed Suppliers

DEVELOPMENTS

5 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

INTERMEDIATES

2 Suppliers

DOSSIERs // Finished Dosage Forms

47 Dossiers

13 FDA Orange Book

10 Europe

6 Canada

7 South Africa

11 Listed Dossiers

DRUG PRODUCT COMPOSITION

POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL;250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INTRAVENOUS - EQ 500MG BASE/VIAL;500MG/VIAL

RELATED EXCIPIENT COMPANIES

Suppliers

1 SPI Pharma

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions

10 Finished Drug Prices

MARKET PLACE

13 APIs

4 DOSSIERS // FDF

PATENTS

3 US Patents

2 US Exclusivities

ANALYTICAL SOLUTION(s)

1 EDQM Standards

1 USP Standards

1 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilation & Company Tracker #PharmaFlow

20 News

DSSTox_CID_3143

MSD MERCK CO

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

GAIN

2029-07-16

212819

1

MSD MERCK CO

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

NCE

2024-07-16

212819

1

POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL;250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons